AVTR vs. TEVA: Avantor vs. Teva Pharmaceutical Stock Comparison
How do Avantor (AVTR) and Teva Pharmaceutical (TEVA) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.
Company Profile
Avantor (AVTR) and Teva Pharmaceutical (TEVA) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but AVTR is classified in Life Sciences Tools & Services while TEVA is classified in Pharmaceuticals.
Avantor (AVTR) trades as ordinary local shares, while Teva Pharmaceutical (TEVA) trades as an ADR — compare with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.
| Profile Item | AVTR | TEVA |
|---|---|---|
| Name | Avantor, Inc. | Teva Pharmaceutical Industries Ltd. ADR |
| Country/Region | United States | Israel |
| GICS Sector | Health Care | Health Care |
| GICS Industry Group | Pharmaceuticals, Biotechnology & Life Sciences | Pharmaceuticals, Biotechnology & Life Sciences |
| GICS Industry | Life Sciences Tools & Services | Pharmaceuticals |
| GICS Sub-Industry | Life Sciences Tools & Services | Pharmaceuticals |
| Market Capitalization | 10.48 billion USD | 49.72 billion USD |
| Currency | USD | USD |
| Exchange | NYSE | NYSE |
| Listing Date | May 17, 2019 | February 16, 1982 |
| Security Type | Common Stock | ADR |
Price Performance
Cumulative Growth
Trailing Returns
Calendar-Year Returns
Performance Metrics
| Metric | AVTR | TEVA |
|---|---|---|
| Total Return (1Y) | 36.41% | 79.58% |
| Total Return (3Y, Annualized) | -5.02% | 69.94% |
| Total Return (5Y, Annualized) | -16.62% | 35.86% |
Risk Profile
Drawdown History
Return Distribution
Risk Metrics
| Metric | AVTR | TEVA |
|---|---|---|
| Volatility (1Y, Annualized) | 43.39% | 33.95% |
| Beta (5Y) | 0.94 | 0.96 |
| Max Drawdown (5Y) | -82.42% | -43.70% |
| Avg. Volume (3M) | 8.56M | 5.91M |
Risk-Adjusted Performance
Risk-Return Positioning
Risk-Adjusted Metrics
| Metric | AVTR | TEVA |
|---|---|---|
| Sharpe Ratio (1Y) | 0.74 | 2.22 |
| Sortino Ratio (1Y) | 1.17 | 3.94 |
Profitability
ROE (TTM)
Teva Pharmaceutical (TEVA) at 6.65% sits in the top ROE quartile, while Avantor (AVTR) at 5.91% is closer to the peer norm — stronger capital efficiency for TEVA.
AVTR
Pharmaceuticals, Biotechnology & Life Sciences industry group
5.91%
- Max
- 109.18%
- Q3
- 6.23%
- AVTR
- 5.91%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
TEVA
Pharmaceuticals, Biotechnology & Life Sciences industry group
6.65%
- Max
- 109.18%
- TEVA
- 6.65%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
Net Margin (TTM)
Avantor (AVTR) at 5.08% retains a top-quartile share of revenue as profit, ahead of Teva Pharmaceutical (TEVA) at 2.94%, which keeps about the industry-typical share.
AVTR
Pharmaceuticals, Biotechnology & Life Sciences industry group
5.08%
- Max
- 18.05%
- AVTR
- 5.08%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
TEVA
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.94%
- Max
- 18.05%
- Q3
- 4.78%
- TEVA
- 2.94%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
Operating Margin (TTM)
Teva Pharmaceutical (TEVA) at 27.40% operates in the top operating margin quartile, ahead of Avantor (AVTR) at 8.19%, which runs around its industry’s norm.
AVTR
Pharmaceuticals, Biotechnology & Life Sciences industry group
8.19%
- Max
- 83.12%
- Q3
- 14.77%
- AVTR
- 8.19%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
TEVA
Pharmaceuticals, Biotechnology & Life Sciences industry group
27.40%
- Max
- 83.12%
- TEVA
- 27.40%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
Profitability Metrics
| Metric | AVTR | TEVA |
|---|---|---|
| ROE (TTM) | 5.91% | 6.65% |
| ROA (TTM) | 2.83% | 5.35% |
| Net Margin (TTM) | 5.08% | 2.94% |
| Operating Margin (TTM) | 8.19% | 27.40% |
| Gross Margin (TTM) | 31.59% | 53.51% |
Growth
Revenue Growth
Teva Pharmaceutical (TEVA) at 4.31% is around its peer norm for revenue growth, while Avantor (AVTR) at -3.41% drops into the bottom quartile, signaling weaker demand or pricing momentum.
EPS Growth
Only one side can be read here: Avantor (AVTR) reports EPS growth of -175.00%, ranked against its industry; Teva Pharmaceutical (TEVA) has no EPS growth figure this period.
Growth Metrics
| Metric | AVTR | TEVA |
|---|---|---|
| Revenue Growth (YoY) | -3.41% | 4.31% |
| Revenue Growth (3Y CAGR) | -4.46% | 4.96% |
| EPS Growth (YoY) | -175.00% | -- |
| EPS Growth (3Y CAGR) | -- | -- |
Financial Strength
Current Ratio (MRQ)
Both Avantor (AVTR) at 1.89 and Teva Pharmaceutical (TEVA) at 0.95 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.
AVTR
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.89
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- Q1
- 2.47
- AVTR
- 1.89
- Min
- 0.10
TEVA
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.95
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- Q1
- 2.47
- TEVA
- 0.95
- Min
- 0.10
Debt / Equity (MRQ)
Avantor (AVTR) at 0.63 is near its industry mid-range for debt-to-equity ratio, while Teva Pharmaceutical (TEVA) at 2.13 sits above its benchmark range, pointing to a heavier debt load relative to equity.
AVTR
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.63
- Max
- 1.42
- Q3
- 0.65
- AVTR
- 0.63
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
TEVA
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.13
- TEVA
- 2.13
- Max
- 1.42
- Q3
- 0.65
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
Financial Strength Metrics
| Metric | AVTR | TEVA |
|---|---|---|
| Current Ratio (MRQ) | 1.89 | 0.95 |
| Debt / Equity (MRQ) | 0.63 | 2.13 |
| Net Debt / EBITDA | 3.40 | 2.93 |
Dividends
Dividend Yield (TTM)
Neither Avantor (AVTR) nor Teva Pharmaceutical (TEVA) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.
AVTR
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- AVTR
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
TEVA
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- TEVA
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Payout Ratio (TTM)
Neither Avantor (AVTR) nor Teva Pharmaceutical (TEVA) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.
AVTR
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- AVTR
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
TEVA
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- TEVA
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Metrics
| Metric | AVTR | TEVA |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.00% |
| Dividend Payout Ratio (TTM) | 0.00% | 0.00% |
Valuation
P/E Ratio (TTM)
Avantor (AVTR) at 30.94 is near its industry’s usual P/E ratio, while Teva Pharmaceutical (TEVA) at 99.09 sits above its peer range — an unusually expensive price for TEVA’s trailing earnings.
AVTR
Pharmaceuticals, Biotechnology & Life Sciences industry group
30.94
- Max
- 85.34
- Q3
- 43.46
- AVTR
- 30.94
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
TEVA
Pharmaceuticals, Biotechnology & Life Sciences industry group
99.09
- TEVA
- 99.09
- Max
- 85.34
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
P/S Ratio (TTM)
Both Avantor (AVTR) at 1.58 and Teva Pharmaceutical (TEVA) at 2.89 fetch a relatively low price per dollar of sales, landing in the cheaper P/S ratio quartile of their industries.
AVTR
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.58
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- Q1
- 3.01
- AVTR
- 1.58
- Min
- 0.01
TEVA
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.89
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- Q1
- 3.01
- TEVA
- 2.89
- Min
- 0.01
P/B Ratio (MRQ)
On P/B ratio, both Avantor (AVTR) at 1.80 and Teva Pharmaceutical (TEVA) at 6.23 are valued close to their industries’ norm against book — neither stands out from peers.
AVTR
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.80
- Max
- 13.53
- Q3
- 6.54
- Median
- 3.25
- AVTR
- 1.80
- Q1
- 1.69
- Min
- -5.59
TEVA
Pharmaceuticals, Biotechnology & Life Sciences industry group
6.23
- Max
- 13.53
- Q3
- 6.54
- TEVA
- 6.23
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
Valuation Metrics
| Metric | AVTR | TEVA |
|---|---|---|
| P/E Ratio (TTM) | 30.94 | 99.09 |
| P/S Ratio (TTM) | 1.58 | 2.89 |
| P/B Ratio (MRQ) | 1.80 | 6.23 |
| Free Cash Flow Yield (TTM) | 4.21% | 3.00% |